0.00Open0.00Pre Close0 Volume0 Open Interest4.00Strike Price0.00Turnover0.00%IV-153.16%PremiumDec 20, 2024Expiry Date2.42Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.41Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Regulus Therapeutics Stock Discussion
📊⚡️📊
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vanguard loaded
Regulus Therapeutics Inc., a biopharmaceutical company listed on Nasdaq under the ticker symbol RGLS, has recently announced positive topline results from the third cohort of patients in its Phase 1b Multiple-Ascending Dose (MAD) clinical trial of RGLS8429. This investigational drug is being developed for the treatment of ...
No comment yet